Study of Two Fasting Procedures Before Gastroscopy: 6 Hours Versus 2 Hours for Clear Fluids (GASTROPREP)
Upper gastrointestinal endoscopy is the key examination for screening for precancerous and cancerous lesions of the esophagus and stomach. This study aims to describe the quality of the visualization of the esophageal and gastric mucosa, the safety of use of two fasting procedures before gastroscopy and the feeling of patients. The population evaluated here concerns cirrhotic patients, at high risk of developing a precancerous lesion of the upper gastrointestinal tract.
The investigator carries out a prospective, monocentric (Besançon CHRU), interventional and randomized study according to two fasting procedures before gastroscopy: 6 hours (F6 group) versus 2 hours (F2 group) for clear fluids. The primary endpoint was to describe and compare the quality of visualization of the esophageal and gastric mucosa, graded from A (good quality) to C (poor quality) according to a score. developed by Elvas et al. (Endoscopy 2017).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Besançon, France, 25000
- Centre Hospitalier Universitaire
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years,
- Male or female
- Cirrhosis based on radiological, clinical, biological or histological criteria
Exclusion Criteria:
- Diabetes for more than 10 years;
- Under 18 years of age;
- History of inhalation
- Patients in whom the gastrointestinal anatomy has not been retained
- Subjects who were unlikely to cooperate with the study and / or in whom poor cooperation was anticipated by the investigator
- Pregnant women Patients taking drugs that may slow down gastric Emptying such as: anticholinergic drugs, phenothiazines, antidepressants History of esophageal radiotherapy Unsubstituted hypothyroidism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Fasting 2 hours
|
fasting before gastrointestinal endoscopy
|
|
Other: Fasting 6 hours
|
fasting before gastrointestinal endoscopy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Score for quality of visualization of the esophageal and gastric mucosa
Time Frame: During endoscopy
|
The score is graded from A (good quality) to C (poor quality) according to a score developed by Elvas et al. (Endoscopy 2017).
|
During endoscopy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire concerning security
Time Frame: During endoscopy
|
Questionnaire filled by the investigator concerning the side effectets observed or not observed
|
During endoscopy
|
|
Questionnaire concerning patient confort during fasting
Time Frame: The day of the endoscopy
|
Snsations felt or not felt by the patients
|
The day of the endoscopy
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P/2017/343
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis
-
NCT03911037UnknownDecompensated Cirrhosis of Liver
-
NCT05740358Active, not recruitingCirrhosis | Autoimmune Hepatitis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary
-
NCT05832229RecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic
-
NCT04956328Recruiting
-
NCT07131280Not yet recruiting
-
NCT06306781Not yet recruiting
-
NCT06134544RecruitingDecompensated Cirrhosis
-
NCT05734001Recruiting
Clinical Trials on fasting
-
NCT04998591TerminatedFertility Issues | Fertility Disorders | IVF | Sub Fertility, Female | Sub-fertility
-
NCT01954836Completed
-
NCT03703115WithdrawnPolycystic Ovary Syndrome | Infertility
-
NCT06737224RecruitingGlucose Tolerance | Fasting | Immune Function
-
NCT00569959CompletedDiabetes Mellitus | Hyperlipidemia | Normal Glucose Metabolism
-
NCT04760847Not yet recruitingPancreatitis | Pancreatitis, Chronic | Pancreatitis, Acute | Pancreas Disease | Acute Recurrent Pancreatitis